Together, these results suggest that high CIP2A expression in lung cancer may be associated with enhanced angiogenesis (CD31), increased epithelial markers (E-cadherin), and suppression of AMPK-mediated metabolic regulation, providing mechanistic insights into its potential role in tumor progression. This evidence concerns the gene PECAM1 and lung cancer.